HRT Patches Could Revolutionise Prostate Cancer Treatment, Major Study Finds
A groundbreaking study from University College London suggests hormone replacement therapy patches, identical to those prescribed for menopausal women, could become a standard treatment for prostate cancer. The research indicates these transdermal patches work just as effectively as current hormone injections at halting disease progression while causing fewer adverse effects and reducing the need for frequent hospital visits.
Transforming Treatment for the UK's Most Common Male Cancer
Prostate cancer remains the most prevalent cancer among men in the United Kingdom, with approximately 63,000 new cases and 12,000 fatalities recorded annually. Despite its high incidence rate, unlike breast, bowel and lung cancers, there is still no national screening programme established for prostate cancer detection in the UK.
The comprehensive study, published in the prestigious New England Journal of Medicine, involved 1,360 men with an average age of 72 from cancer centres across the country. All participants had locally advanced prostate cancer, meaning the disease had spread just beyond the prostate gland itself.
Comparing Two Hormone Therapy Approaches
Researchers conducted a direct comparison between standard hormone injections and innovative patch treatment. The conventional approach involves injections that directly block testosterone production, while the experimental method utilises patches delivering oestradiol – a form of the female sex hormone oestrogen – through the skin, which indirectly suppresses testosterone levels.
The findings revealed the patches demonstrated equivalent effectiveness to injections in controlling cancer progression. This represents a significant breakthrough in prostate cancer management, potentially offering patients a more tolerable treatment option with comparable therapeutic benefits.
Reducing Treatment Burden and Side Effects
Standard hormone injections for prostate cancer frequently trigger numerous undesirable side effects including debilitating hot flushes, bone weakening, and increased cardiovascular risk factors such as elevated cholesterol, blood sugar and blood pressure levels. The study discovered that patches caused substantially fewer of these problematic effects.
However, researchers noted one significant drawback: patches were associated with a higher incidence of gynaecomastia, a condition involving painful swelling of breast tissue in men. Despite this particular side effect, the overall side effect profile appeared more favourable with patch therapy.
Convenience and Quality of Life Improvements
Beyond medical benefits, the patch treatment offers substantial practical advantages. Traditional injections necessitate regular visits to general practitioners or hospital clinics, creating logistical challenges for patients. In contrast, hormone patches can be self-administered at home, dramatically reducing treatment burden and healthcare system pressures.
Lead author Professor Ruth Langley from the MRC Clinical Trials Unit at UCL emphasised the importance of patient choice: 'We believe our findings should allow men with locally advanced prostate cancer to choose the hormone therapy that suits them best. For some men, side effects like hot flushes can be very debilitating, so the patches could greatly improve quality of life.'
Expert Endorsement and Patient-Centred Care
Caroline Geraghty, senior specialist nurse manager at Cancer Research UK, welcomed the findings: 'This trial shows hormone patches are just as effective as traditional injections at controlling prostate cancer, while being much easier and gentler to administer. This could give men greater choice over their treatment, helping them to live not just longer lives, but better lives.'
Simon Grieveson, assistant director of research at Prostate Cancer UK, highlighted the significance of treatment options: 'Results from trials have shown that hormone patches like these are just as effective at delaying cancer progression. They also resulted in fewer men experiencing hot flushes, although breast swelling was more common. These patches are more convenient and less invasive, and could give men greater choice based on what matters most to them.'
The Ongoing Screening Debate
This treatment breakthrough emerges against the backdrop of continuing debate about prostate cancer screening in the UK. The UK National Screening Committee has previously expressed concerns that nationwide screening using the prostate-specific antigen test might cause more harm than benefit due to its reliability issues.
The PSA test produces both false positives and false negatives, potentially leading to unnecessary treatments for slow-growing tumours with significant side effects including incontinence and erectile dysfunction. Conversely, some medical experts advocate for expanded testing, particularly among higher-risk groups such as men with family histories or specific genetic mutations.
A major UK trial named Transform is currently underway to evaluate whether a combination of diagnostic approaches – including genetic screening and rapid MRI scans – could form the foundation for a national screening programme. Researchers anticipate this comprehensive assessment could pave the way for life-saving changes within the coming years.
Understanding Prostate Cancer
Prostate cancer develops when cells within the prostate gland grow uncontrollably. The prostate itself is a small gland, roughly walnut-sized, situated at the base of the bladder. This disease predominantly affects older men, with the highest incidence rates occurring in those aged over 75.
Key risk factors include:
- Advancing age
- Family history and genetic predisposition
- Ethnic background, with higher risk among black men
- Lifestyle factors and other health conditions
Prostate cancer typically presents no symptoms during early stages, with noticeable symptoms usually appearing only when tumours grow sufficiently large to affect urinary function. This silent progression underscores the importance of both effective treatments and improved detection methods.
